MORF-057

The FDA has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for treating moderately to severely active Crohn's disease in adults, expanding its use for inflammatory bowel disease.

Schrödinger expands collaboration with Otsuka Pharmaceutical and anticipates $150 million upfront payment from Novartis in Q1 2025.

The Crohn's disease market is experiencing growth, driven by increasing prevalence and advances in treatment options, with the market size expected to increase from USD ~9,000 million in 2023.

Johnson & Johnson has submitted sBLAs to the FDA for Tremfya (guselkumab) to treat moderate-to-severe plaque psoriasis in children aged 6 and older.